# NCT04281498 (NCT04281498)

> Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04281498
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: John Mascarenhas
- Conditions: Accelerated/Blast-phase Myeloproliferative Neoplasm; Chronic-phase Myelofibrosis; IDH2 Mutation
- Interventions: Ruxolitinib; Enasidenib
- Enrollment: 6
- Primary outcome: Number of MPN Participants With Response

## Indexed commentary on NCT04281498 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04281498